
Xspray Pharma Q4 2023 - NDA-resubmission accepted by the FDA

Redeye updates its outlook for Xspray following its Q4 report, and we highlight that the recently announced PDUFA-date at the end of July marks a significant catalyst for the stock.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Xspray Pharma Q4 2023 - NDA-resubmission accepted by the FDA](#)